13G Filing: Sabby Capital and Arca Biopharma Inc. (ABIO)
Sabby Healthcare Master Fund, Ltd | 0 | 446,052 | 0 | 446,052 | 446,052 | 3.80 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 00211Y407 1.
Arca Biopharma Inc. (ABIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 54,700 | $97,366 | +828% | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 1,224 | $2,179 | -81% | 0% |
| 3. | Renaissance Technologies Jim Simons | 65,699 | $116,000 | +15% | 0% |
| 4. | Newtyn Management Noah Levy And Eugene Dozortsev | 0 | $0 | -100% | 0% |
| 5. | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.45 | 94,537 | Large Shareholder | 1,891,312 | 2024-07-11 | Filing | |
| $3.46 | 21,963 | Large Shareholder | 1,796,775 | 2024-07-10 | Filing | |
| $3.46 | 33,500 | Large Shareholder | 1,774,812 | 2024-07-10 | Filing | |
| $3.43 | 16,917 | Large Shareholder | 1,741,312 | 2024-07-09 | Filing | |
| $3.54 | 17,600 | Large Shareholder | 1,724,395 | 2024-07-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.50 | 482 | Officer | 13,153 | 2018-04-03 | Filing | |
| $0.50 | 1,114 | Officer | 0 | 2018-04-02 | Filing | |
| $0.72 | 410 | Officer | 13,635 | 2018-02-28 | Filing | |
| $0.53 | 161 | Officer | 1,114 | 2018-02-27 | Filing | |
| $0.53 | 41,331 | Large Shareholder | 0 | 2018-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,000,452 | $6,800,768 | 7.06% | |
| 2. | 1,410,143 | $2,397,243 | 1.59% | |
| 3. | 706,930 | $1,201,781 | 0.91% | |
| 4. | 453,598 | $771,117 | 0% | |
| 5. | 231,911 | $394,249 | 0% |
News See All
Venrock's Latest Pick Shows There Are More Biotech Opportunities to Explore
Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks.
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.